Phospholemman Modulates the Gating of Cardiac L-Type Calcium Channels  by Wang, Xianming et al.
Biophysical Journal Volume 98 April 2010 1149–1159 1149Phospholemman Modulates the Gating of Cardiac L-Type Calcium
ChannelsXianming Wang,†6 Guofeng Gao,†6 Kai Guo,†§ Viktor Yarotskyy,‡ Congxin Huang,§ Keith S. Elmslie,‡
and Blaise Z. Peterson†*
†Department of Cellular and Molecular Physiology, and ‡Department of Anesthesiology and Pharmacology, Pennsylvania State University
College of Medicine, Hershey, Pennsylvania; and §Renmin Hospital, Cardiovascular Research Institute, Wuhan University, Wuhan, Hubei,
People’s Republic of ChinaABSTRACT Ca2þ entry through L-type calcium channels (CaV1.2) is critical in shaping the cardiac action potential and initiating
cardiac contraction. Modulation of CaV1.2 channel gating directly affects myocyte excitability and cardiac function. We have
found that phospholemman (PLM), a member of the FXYD family and regulator of cardiac ion transport, coimmunoprecipitates
with CaV1.2 channels from guinea pig myocytes, which suggests PLM is an endogenous modulator. Cotransfection of PLM in
HEK293 cells slowed CaV1.2 current activation at voltages near the threshold for activation, slowed deactivation after long
and strong depolarizing steps, enhanced the rate and magnitude of voltage-dependent inactivation (VDI), and slowed recovery
from inactivation. However, Ca2þ-dependent inactivation was not affected. Consistent with slower channel closing, PLM signif-
icantly increased Ca2þ inﬂux via CaV1.2 channels during the repolarization phase of a human cardiac action potential waveform.
Our results support PLM as an endogenous regulator of CaV1.2 channel gating. The enhanced VDI induced by PLM may help
protect the heart under conditions such as ischemia or tachycardia where the channels are depolarized for prolonged periods of
time and could induce Ca2þ overload. The time and voltage-dependent slowed deactivation could represent a gating shift that
helps maintain Ca2þ inﬂux during the cardiac action potential waveform plateau phase.INTRODUCTIONVoltage-gated calcium channels regulate important physio-
logical processes such as excitation-contraction coupling,
neurotransmitter release, hormone secretion, and gene
expression (1). The activity of L-type calcium channels
(CaV1.2) is vital for the maintenance of normal excitability
and Ca2þ homeostasis in the heart. The dysregulation of
CaV1.2 channels can lead to severe cardiac pathologies such
as long QT syndrome (2–4). The modulation of CaV1.2 chan-
nels by signaling pathways and associated proteins is impor-
tant for many physiological and pathophysiological processes
(5–7). The gating of thea1 subunit of the cardiac CaV1.2 chan-
nels is complex and tightly regulated (8). Drugs that target the
CaV1.2 a1 subunit are used routinely to treat cardiovascular
diseases such as hypertension and angina pectoris (9,10),
and a1-associated proteins represent an important mechanism
by which CaV1.2 channels are regulated (8,11,12). Thus,
drugs that target the pore-forming a1 subunit or its associated
regulatory proteins have high clinical relevance.
The FXYD family of ion transport regulators was first
defined based on an invariant peptide sequence, known as
the FXYD motif (13). The FXYD motif is located on the
N-termini of these single membrane spanning proteins and
consists of five amino acids (Pro-Phe-X-Tyr-Asp). Seven
members of the FXYD family (FXYD1–FXYD7) have
been identified in mammals and are distributed widely inSubmitted August 7, 2009, and accepted for publication November 18, 2009.
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0006-3495/10/04/1149/11 $2.00tissues that carry out fluid and solute transport (kidney, colon,
breast/mammary gland, pancreas, prostate, liver, lung, and
placenta), and in electrically excitable tissues (nervous system
and muscle) (13,14).
FXYD1, also known as phospholemman (PLM), is local-
ized to the sarcolemma and transverse tubules of cardiac my-
ocytes where it regulates [Ca2þ]i through its interactions with
Na,K-ATPase (NKA) (15–17) and the Naþ/Ca2þ exchanger
(NCX) (18–20). As the primary pathway controlling Ca2þ
entry into the cardiac myocyte, the observed PLM-dependent
changes in [Ca2þ]i merit the investigation of L-type calcium
channels as a possible target for PLM modulation. We
present what we believe to be the first report that currents
through cardiac CaV1.2 channels are modulated by PLM.
Our detailed kinetic analysis demonstrates that PLM slows
the activation, slows deactivation in a time and voltage
dependent manner, and enhances voltage-dependent inacti-
vation. Slowed deactivation is predicted to enhance the rela-
tive Ca2þ entry during the repolarization phase of the cardiac
action potential. These dynamic PLM-dependent changes in
CaV1.2 channel gating are expected to directly alter cell
excitability, Ca2þ homeostasis and cardiac function.MATERIALS AND METHODS
Coimmunoprecipitations and Western blot
analysis
Antibodies
The mouse monoclonal anti-Flag M2 (Sigma-Aldrich, St. Louis, MO);
rabbit polyclonal anti-CaV1.2 (Calbiochem, San Diego, CA); mousedoi: 10.1016/j.bpj.2009.11.032
1150 Wang et al.monoclonal anti-CaV1.2 (clone L57/46, UC Davis/National Institutes of
Health NeuroMab Facility; rabbit polyclonal anti-CaV2.1 (Chemicon,
Temecula, CA); rabbit polyclonal anti-PLM (C2) (a generous gift from
Dr. J. Y. Cheung, Thomas Jefferson University). Pre-immune mouse IgG,
pre-immune rabbit IgG, and protein A/G plus agarose were from Santa
Cruz Biotech (Santa Cruz, CA). Isolation of guinea pig ventricular myocytes
and subsequent coimmunoprecipitation experiments were carried out as
described previously (16). Coimmunoprecipitation experiments carried out
on HEK293 cell lysates were carried out as described previously (21).
Whole-cell patch-clamp electrophysiology
Whole-cell patch-clamp experiments were carried out as described previ-
ously (22). Briefly, HEK293 cells were transiently transfected with cDNAs
encoding CaV1.2 (23) or CaV2.1 (GenBank No. AF055477; generously
provided by Dr. Lucie Parent), the auxiliary subunits, a2d (24) and b1b
(25), GFP (Clontech Laboratories, Mountain View, CA) and either PLM/
pAdTrack or empty pAdTrack vector (both generously provided by
Dr. Joseph Y. Cheung). The majority of recordings used a bath solution con-
taining (mmol/L): 130 N-methyl-D-glutamine (NMG)-aspartate, 10 HEPES,
10 4-aminopyridine, 10 glucose, 1 MgCl2, and 5 or 10 CaCl2/BaCl2 (Ba
2þ
was used unless noted otherwise). Internal solutions contained (mmol/L):
140 NMG-MeSO3, 5 EGTA, 1 MgCl2, 4 Mg-ATP, and 10 HEPES. For
recording CaV1.2 currents activated by a human cardiac action potential
waveform, the bath solution contained (mmol/L): 140 NMG-Cl, 10 NMG-
HEPES and 5 CaCl2, and the internal solution contained (mmol/L): 104
NMG-Cl, 14 Creatine-PO4, 6 MgCl2, 10 NMG-HEPES, 10 NMG-EGTA,
5 Tris-ATP, 0.3 Tris-GTP. Data were acquired using either a HEKA
EPC-9/2 amplifier and PULSE/PULSEFIT software (ALA Scientific Instru-
ments, Farmingdale, NY) or an Axopatch 200A (Molecular Devices, Sunny-
vale, CA) and S5 data acquisition software (Dr. Stephen Ikeda, National
Institutes of Health National Institute on Alcohol Abuse and Alcoholism,
Bethesda, MD). Leak and capacitive transients were corrected by P/4
compensation and series resistance was compensated at 70%. Tail currents
were sampled at 50 kHz, and filtered at 5.0 kHz. All the other currents
were sampled at 20 kHz, and filtered at 3.0 kHz. Data were analyzed using
Fitmaster (ALA Scientific Instruments) and Origin (Originlab, Northamp-
ton, MA) or IgorPro (WaveMetrics, Lake Oswego, OR). Results were
compared using unpaired Student’s t-test or ANOVA, as indicated, and
were expressed as the mean5 SD, where p< 0.05 is considered significant.RESULTS
Association of PLM with native and exogenously
expressed CaV1.2 channels
Recent work showing that PLM plays an important role in
regulating excitability and Ca2þ homeostasis in myocardium
(15–19,26) prompted us to investigate the potential role
PLM may play in regulating cardiac CaV1.2 channels. We
carried out coimmunoprecipitation (co-IP) experiments to
test for the potential association of PLM with CaV1.2 chan-
nels using solubilized membranes from guinea pig cardiac
myocytes and lysates of transfected HEK293 cells (Fig. 1).
As expected, CaV1.2 and PLM were observed when the solu-
bilized membranes were subjected to Western blot analysis
(Fig. 1 A, lane 1). Immunoprecipitation (IP) experiments
using the anti-CaV1.2 antibodies coprecipitated PLM
demonstrating an association between these proteins
(Fig. 1 A, lane 4). Both CaV1.2 and PLM were absent in
the insoluble and post-IP fractions (Fig. 1 A, lanes 2 and
3) and neither protein was detected in the IgG control laneBiophysical Journal 98(7) 1149–1159(Fig. 1 A, lane 5). The plasma membrane Ca2þ-ATPase
(PMCA) has been shown previously to have no interaction
with PLM (16), was used here as a negative control
(Fig. 1 B). As shown previously (15,16,19), we found that
PLM was able to co-IP with NCX1 (Fig. 1 C) or NKA a1
subunit (not shown). These results indicate that the associa-
tion between CaV1.2 and PLM is specific.
We were interested determining whether PLM was capable
of associating with other members of the CaV superfamily.
Therefore, we carried out co-IP experiments using HEK293
cells transiently expressing either Flag-tagged CaV1.2
(Fig. 1 D), or CaV2.1 (Fig. 1 E) channels plus PLM. Consis-
tent with our findings using guinea pig membranes, we found
that co-IP was obtained for PLM with an anti-Flag Ab only in
cells expressing both Flag-tagged CaV1.2 channels and PLM
(Fig. 1D), whereas no PLM co-IP was observed when using
the CaV2.1 Ab (Fig. 1 E). The reverse experiment of using
the PLM Ab showed a co-IP of CaV1.2, but not CaV2.1 (not
shown). Thus, PLM seems to specifically interact with
CaV1.2 channels.PLM speciﬁcally alters CaV1.2 channel gating
The association between PLM and CaV1.2 channels suggests
the potential for gating modulation, which was examined
using the HEK293 cell heterologous expression system.
Whole-cell recordings from HEK293 cells expressing
CaV1.2 (Fig. 2, A–C) or CaV2.1 (Fig. 2, D–F) channels in
the absence (empty vector) and presence of PLM were con-
ducted. We found that PLM slows CaV1.2 channel activation
and left-shifts the activation versus voltage relationship
(Fig. 2, A and C). These currents were generated by 25 ms
depolarizing pulses to minimize the effect of voltage-depen-
dent inactivation in our experiments (see below), and Ba2þ
was used as the charge carrier to eliminate Ca2þ-dependent
inactivation (12,27–29). The sample traces in Fig. 2 A
show normalized currents (at 10 mV) from different cells
(5 PLM) to highlight the effect of PLM to slow activation.
The activation versus voltage relationship measured from tail
currents was left-shifted >20 mV so that the half activation
voltage (Vh) changed from 25.0 to 4.1 mV with PLM and the
relationship exhibited a much steeper slope factor (e-fold/
23.3 vs. 12.9 mV) (Fig. 2 C). Consequently, at þ10 mV,
<40% of the channels were activated in the absence of
PLM, whereas nearly 70% of the channels are activated in
the presence of PLM. In contrast to CaV1.2, PLM failed to
alter the activation kinetics (Fig. 2 D) or the voltage-depen-
dence of activation of neuronal CaV2.1 (Fig. 2, E and F) or
CaV2.2 (not shown) channels. Thus, PLM selectively associ-
ates with and modulates CaV1.2 but not CaV2.1 and CaV2.2
channels.
The voltage-dependence of PLM-induced slowed CaV1.2
channel activation was determined using currents generated
during the I/V protocol (Fig. 3). The speed of activation
was quantified by measuring the time required for the current
FIGURE 1 Association of PLM with native and exoge-
nously expressed CaV1.2 channels. IP experiments were
carried out on solubilized membranes derived from (A–C)
guinea pig ventricular myocytes and (D and E) HEK 293
cell lysates using (A) anti-CaV1.2, (B, negative control)
anti-PMCA antibody, (C, positive control) anti-NCX1,
(D) Anti-Flag, and (E) anti-CaV2.1 antibodies. (A–C)
Control lanes: Pre-IP: solubilized protein before IP; Insol:
insoluble protein removed by centrifugation; Supnt: super-
natant after IP; IgG: IgG control. Blots were probed with
antibodies against PLM (lower panels) and CaV1.2,
PMCA or NCX, as indicated (upper panels). (D) IP exper-
iments carried out on lysates prepared from HEK293cells
expressing CaV1.2, PLM or both as indicated using mouse
monoclonal anti-Flag antibody (lanes 1–3) or mouse pre-
immune IgG (lane 4), followed by immunoblot analysis
using antibodies against PLM (upper panel) and CaV1.2
(lower panel). (E) Similar to D, except cells were trans-
fected with cDNAs encoding CaV2.1, PLM, or both and
IP was carried out using antibodies against CaV2.1.
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Activation was significantly slowed at hyperpolarized volt-
ages close to the threshold for channel activation, but no sig-
nificant effect was observed at voltages R0 mV (Fig. 3 B).
It is possible that the effect of PLM on activation kinetics
is voltage dependent. However, inactivation has been shown
to impact the measurement of activation kinetics (30), so this
interpretation is confounded by our observation that PLM
expression also enhances voltage dependent inactivation at
more depolarized voltages (see below).PLM slows deactivation of CaV1.2 channels
Activation and deactivation share the same gating machinery
operating in opposite directions. Thus, the PLM effect onactivation may also be reflected in altered deactivation
kinetics. Fig. 4 A shows superimposed tail currents from
CaV1.2 channels 5 PLM to highlight the effect of PLM
on deactivation. Tail current deactivation was fit using
a single exponential equation to determine the deactivation
t (tDeact). Using the I/V protocol (Fig. 2), tDeact was deter-
mined following a range of depolarizing voltages and
showed an increase with voltage that was enhanced by
PLM (Fig. 4 B). tDeact was significantly larger at all voltages
for (þ)PLM compared with ()PLM. These findings suggest
that the interaction of PLM with CaV1.2 channels slows
channel closing.
It is well established that deactivation is slowed when
CaV1.2 channels switch from mode 1 (low Po) into mode 2
(high Po) gating (31,32) and this gating switch is bothBiophysical Journal 98(7) 1149–1159
FIGURE 2 PLM alters the kinetics and voltage-depen-
dence of CaV1.2 channel activation. Ba
2þ currents evoked
by 25 ms depolarizing steps to 10 mV in the absence
(()PLM; black) and presence ((þ)PLM; gray) for (A)
CaV1.2 and (D) CaV2.1 channels were normalized to
current amplitudes measured at the end of each step.
Current-voltage relationships were generated 5 PLM
by a series of 25 ms step pulses ranging from 60 to
þ50 mV from a holding potential of 100 mV for (B)
CaV1.2 and (E) CaV2.1. Steady-state activation curves
measured from tail currents are left-shifted in the presence
of PLM for (C) CaV1.2, but not (F) CaV2.1 channels. Tail
currents were measured at 50 mV after a series of 25 ms
step pulse 5 from 100 to þ100 mV, and the data were
fitted with a Boltzmann equation (smooth lines) to generate
the half activation voltage (Vh) and slope factor (k). For
CaV1.2: Vh ¼ 25.0 5 2.2 mV and k ¼ 23.3 5 1.57 for
() PLM and Vh ¼ 4.1 5 0.95 mV and k ¼ 12.9 5
0.81 for (þ)PLM. Vh and k for CaV1.2 (but not CaV2.1)
currents are significantly different when measured in the
absence and presence of PLM (p < 0.05, n ¼ 9).
1152 Wang et al.time- and voltage-dependent (32). Thus, if PLM enhances
mode switching, the effect should depend on both step dura-
tion and voltage. We tested this prediction by measuring the
time course (0–250 ms step duration) for slowed deactivation
at10; Fig. 4 C),þ30 (Fig. 4 D), andþ80 mV (Fig. 4 E). As
expected, CaV1.2 currents in the absence of PLM exhibited
a moderate (þ80 mV) time- and voltage-dependent slowing
of deactivation (increased tDeact), suggesting that some
channels are transitioning from mode 1 to mode 2 gating
(Fig. 4, C–E). In the presence of PLM, tDeact was signifi-
cantly larger than ()PLM at þ80 mV for pulse durations
R80 ms, and for þ30 mV at 250 ms. It is noteworthy that
changes in tDeact were not correlated with current amplitude,
indicating that the PLM-induced changes do not result from
voltage-clamp errors. Thus, PLM directly alters CaV1.2
gating by enhancing the voltage- and time-dependent slow-
ing of deactivation, consistent with PLM promoting mode
2 gating. Additional single channel experiments are required
to confirm this intriguing hypothesis.Biophysical Journal 98(7) 1149–1159PLM speciﬁcally enhances voltage-dependent
inactivation of CaV1.2 channels
Examination of the records in Fig. 3 A shows an apparent
enhancement of voltage-dependent inactivation (VDI) at
the most depolarized voltage (20 mV) by PLM. This was
further investigated using longer voltage steps of 300
(Fig. 5 A) and 1000 ms (Fig. 5 C) where VDI is larger and
more easily measured. CaV1.2 channels exhibit little inacti-
vation at the end of a 300 ms step in the absence of PLM,
but inactivation is significantly increased in the presence of
PLM. This was quantified by measuring the fraction of
current remaining at the end of 300 ms (R300), which was
decreased significantly by PLM at voltages Rþ10 mV
(Fig. 5 B). Longer voltage steps (1000 ms) were used to
assess the impact of PLM on the speed of inactivation.
Currents recorded in the presence of PLM inactivated faster
(i.e., decreased inactivation t) (Fig. 5 E) and the fraction of
inactivating current was increased (Fig. 5, C and D),
FIGURE 3 PLM slows activation of CaV1.2 channels. (A) Ba
2þ currents5
PLM were generated by 150 ms voltage steps to 20, 0, and þ20 mV from
a holding potential of 100 mV. Slowing of activation is pronounced at
20 and 0 mV and modest at þ20 mV in the presence of PLM. (B) The
time required for channels to activate from 10 to 90% of the maximum is
plotted versus step voltage 5 PLM. t10–90 is significantly increased in the
presence of PLM at 20 and 10 mV (p < 0.05, n ¼ 9–12).
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O/ I (see below). Ca2þ influx via CaV1.2 channels induces
Ca2þ-dependent inactivation (CDI), but we found that PLM
does not alter CDI (Fig. S1 in the Supporting Material).
Therefore, it seems PLM specifically enhances the speed
of VDI.In addition to a dynamic role in shaping the cardiac action
potential, inactivation is critical for establishing the number
of available channels for activation and, as a result, the
amount of Ca2þ entering the cell during each cardiac cycle
(9,10). We used a standard 3-pulse protocol to determine
the voltage-dependence of channel availability in the
absence and presence of PLM. Peak currents were measured
at 0 mV before and after 30-s steps to voltages ranging from
110 to 0 mV. The postpulse/prepulse ratio (I/Imax) plotted
against voltage (i.e., the h30 curve) is depicted in Fig. 5 F.
PLM steepens the voltage-dependence (Boltzmann slope
factor) and induces a ~10 mV depolarizing shift in the h30
curve. Similar experiments carried out on cells expressing
neuronal CaV2.1 channels in the absence and presence of
PLM exhibited no change in either the half inactivation
voltage or the slope factor (not shown). Thus, PLM seems
to have the capacity to selectively increase the number of
available CaV1.2 channels at depolarized resting membrane
potentials.PLM promotes a deep inactivated state
from which recovery is slow
To better understand how PLM affects inactivation of CaV1.2
channels, we investigated the recovery from inactivation in
the absence and presence of PLM. Inactivation was induced
by 500 ms steps to þ10 mV and quantified as the ratio of
peak postpulse to prepulse currents evoked by steps to
0 mV (Fig. 6 A). The recovery from inactivation time course
was fit by a single exponential function to determine the
recovery t (Fig. 6 B). CaV1.2 channels inactivated by 58%
in ()PLM and 64% in (þ)PLM over the 500 ms step, and
the recovery t was nearly identical for CaV1.2 channels 5
PLM (Fig. 6 B). However, the magnitude of recovery was
significantly reduced in the presence of PLM, suggesting
that PLM places the CaV1.2 channels into a deeper inactivated
state from which recovery is slow. This hypothesis was tested
using longer (20 s) voltage steps to place more channels into
the deeper inactivated state (Fig. 6 C). The fraction of inacti-
vating current resulting from 20 s depolarizing steps to
þ10 mV was significantly larger in the presence of PLM
(98%) than was observed in the absence of PLM (87%)
(Fig. 6 D). Interestingly, 36% of the inactivated CaV1.2 chan-
nels ()PLM had recovered from inactivation by the first
measurement point (30 ms), whereas only 12% of the chan-
nels (þ)PLM had recovered by this time. This fast recovery
is consistent with the recovery t (~20 ms) measured after
the 500 ms inactivating steps (Fig. 6 B), and further supports
our hypothesis that PLM enhances the transition of channels
into a deep inactivated state. CaV1.2 channels5 PLM recov-
ered substantially more slowly after the 20-s step compared to
the 500-ms step (10 s vs. 20 ms), but the recovery rates from
the deep inactivated state were indistinguishable in the
absence and presence of PLM (Fig. 6 D). Therefore, PLM
increases the fraction of channels that enter the deepBiophysical Journal 98(7) 1149–1159
FIGURE 4 PLM slows deactivation of CaV1.2 channels.
(A) Sample tail currents recorded in Ba2þ at 50 mV are
shown after a 100 ms step to þ10 mV. (B) Rate of deacti-
vation5 PLM was evaluated using single exponential fits
of tail currents recorded following voltage steps from 20
to þ80 mV. Values of t versus voltage plots indicate that
PLM slows deactivation at all voltages tested (asterisk)
(n ¼ 5). (C–E) The development of slowed deactivation
was evaluated using standard envelope protocol in the
absence and presence of PLM. Cells were stepped to (C)
10, (D) þ30, and (E) þ80 mV with various durations
(0–250 ms) followed by repolarizing steps to 50 mV.
Tails currents were assessed using single exponential fits
as described in B to determine voltage and time dependent
values for t. Significant differences between () and (þ)
PLM are indicated by an asterisk (n ¼ 4–5).
1154 Wang et al.inactivated state, but does not alter the rate at which the chan-
nels exit from that state.
PLM promotes dynamic changes in Ca2þ entry
PLM-induced slowing of activation and enhancement of
inactivation are expected to combine to reduce Ca2þ entry,
yet the slowing of deactivation is expected to increase
Ca2þ entry during the cardiac action potential (4). Because
PLM-induced changes in activation, inactivation, and deac-
tivation all appear to be voltage- and time-dependent, it is
likely that PLM temporally changes Ca2þ entry during
membrane depolarization and repolarization. The effect of
PLM-induced gating changes on Ca2þ flux can be demon-
strated by comparing difference currents (Fig. 7, A–E) re-
corded in external solution with 10 mM Ca2þ as charge
carrier. The integral of difference current provides a quantita-
tive measure of the changes in the number of Ca2þ ions
permeating the channels 5 PLM at various time points
during the depolarizing step (Fig. 7 F). The integral is nega-
tive at potentials <10 mV, indicating that Ca2þ influx is
reduced during the depolarizing step in the presence of
PLM, which results from slowed activation. The difference
current integral becomes positive at potentials >10 mV
because slowed deactivation greatly increases Ca2þ influx
after the membrane is repolarized.
PLM increases CaV1.2 currents during the
repolarization phase of the cardiac action
potential
It is important to note that the changes in ionic flux eluci-
dated by the difference currents (Fig. 7) clearly highlightBiophysical Journal 98(7) 1149–1159important temporal aspects of PLM-induced changes in
CaV1.2 channel gating. For example, slowed activation
seems to play a dominant role at reducing influx during early
depolarization, but slowed deactivation greatly increases flux
upon repolarization. Given the time and voltage-dependent
slowing of deactivation, we postulated that PLM would
increase calcium entry during the repolarization phase of
the cardiac action potential (cAP) after the ~200 ms plateau
phase. To test this, we recorded CaV1.2 currents 5 PLM
generated by a human cAP waveform in 5 mM Ca2þ
(4,33). The cAP-generated currents 5 PLM exhibited a
stable plateau phase and monotonic decline during repolari-
zation. The effect of PLM on Ca2þ flux during the repolari-
zation phase was assessed by normalizing currents 5 PLM
during the plateau phase, which showed that the duration of
cAP induced-currents is increased when CaV1.2 channels are
expressed with PLM (Fig. 8 A). This enhancement was veri-
fied by integrating the normalized current over the last
200 ms of the cAP (225–425 ms), which showed a significant
increase (þ)PLM. Thus, the interaction of PLM with CaV1.2
channels significantly increases Ca2þ influx during the repo-
larization phase of the cAP, which suggests that PLM plays
a role in setting cAP duration and the QT interval.DISCUSSION
We believe our findings are the first to show that PLM asso-
ciates with and modulates the gating kinetics of CaV1.2
(L-type), but not CaV2.1 (P/Q-type) or CaV2.2 (N-type; not
shown) channels. PLM was found to alter four important
gating processes of CaV1.2 channels: 1), activation kinetics
were slowed at voltages near the threshold for channel
FIGURE 5 PLM enhances VDI of CaV1.2 channels.
Ba2þ currents recorded in the absence and presence of
PLM were generated by either (A) 300 or (C) 1000 ms de-
polarizing steps to þ10 mV in 10 mM Ba2þ. PLM speeds
the rate of inactivation (A and C) and increases the fraction
of inactivating channels at 300 and 1000 ms. (B and D) The
R300 and R1000 values were determined by measuring the
fraction of current remaining at the end of (B) 300 ms
(R300) or (D) 1000 ms (R1000) voltage steps. Significantly
different values between ()PLM and (þ)PLM are indi-
cated by an asterisk (p < 0.05). R300 values are averaged
from 13 cells whereas 12–14 cells were used for the
R1000 values. (E) Single exponential fits through currents
evoked by 1000 ms voltage steps to either þ10 or
þ20 mV indicates that PLM significantly speeds the
kinetics for inactivation (t) at þ20 mV (p < 0.05). (F) A
standard three-pulse protocol consisting of two 150-ms
test pulses to 0 mV (pre- and postpulse) bracketing 30-s
steps to voltages ranging from 110 to 0 mV was used
to assess the effect PLM has on steady-state inactivation.
The interval between each sweep was 80 s to allow chan-
nels to recover from previous inactivation. The postpulse/
prepulse ratio (I/Imax) is plotted versus inactivating voltage.
Single Boltzmann fits were used to determine values for
Vhalf and the slope factor. In the presence of PLM, the
steady-state inactivation curve is right-shifted 7.7 mV
(p < 0.05, n ¼ 4–6), and the slope factor is decreased
from 13.55 2.3 to 9.2 5 2.1 (p < 0.05, n ¼ 4–6).
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voltage steps comparable in magnitude and duration to that
of the human cardiac action potential (cAP); 3), VDI was
enhanced at potentials corresponding to the plateau phase
of the cAP; and 4), an increased number of channels enter
a deep inactivated state from which recovery is slow. Below,
we discuss these PLM-induced changes in CaV1.2 gating in
greater detail and how these PLM-dependent changes are
likely to affect the cardiac action potential and contractility.PLM-induced changes in inactivation
Recent publications have presented evidence highlighting
the importance of calcium channel inactivation to cardiac
function (2–4,34–39), which motivated our investigation of
a potential PLM-dependent modulation of VDI. Over step
depolarizations similar to the plateau phase of the cAP,
PLM accelerates the rate of and increases the magnitude of
VDI. The accelerated VDI at depolarized voltages (i.e.,
þ20 mV) suggests the PLM increases the rate constant gov-
erning transition from the open (O) to inactivated (I) state,whereas the increase in VDI magnitude suggests that PLM
does little to the I/ O rate. This latter point is substantiated
by the observation that PLM enhances the fraction of inacti-
vating channels, which seems to be correlated with increased
occupancy of a deep inactivation state from which recovery
is slow (t > 10 s). We also found that the co-expression of
PLM affects steady-state inactivation by shifting the half
inactivation voltage ~10 mV depolarized and increasing
voltage-dependence inactivation (smaller Boltzmann slope
factor). The combination of right-shifted Vh and steeper
voltage dependence by PLM increases the number of avail-
able channels at voltages near resting membrane potential
(80 to 50 mV). Thus, the association of PLM with
CaV1.2 channels may play an important role in regulating
the number of available channels under physiological and
pathological conditions.
PLM-induced slowing of activation
and deactivation
We observed a PLM-induced slowing of activation, but this
slowing is strongly voltage-dependent and most easilyBiophysical Journal 98(7) 1149–1159
FIGURE 6 PLM promotes a deep inactivated state from
which recovery is slow. (A) Recovery from a short inacti-
vating pulse. Ba2þ currents were evoked using a three-
pulse protocol with 100 ms pre- and postpulses to 0 mV
bracketing a 500-ms inactivating pulse to þ10 mV. The
interval between the inactivation pulse and postpulse
(recovery time) was increased to determine the recovery
time for inactivation. The interval between sweeps was
30 s. CaV1.2 currents (5)PLM were scaled to peak pre-
pulse current and superimposed for easier comparison.
(B) The ratio of Ba2þ currents measured before and after
500 ms inactivating steps (IPost/IPre ratio) is plotted versus
recovery time. Smooth lines are single exponential fits:
t ¼ 30.6 5 5.1 and 27.3 5 4.3 ms for ()PLM and
(þ)PLM respectively (n ¼ 5, not significantly different).
(C) Recovery from a long conditioning pulse. Currents
generated as described for A except inactivation was gener-
ated by a single 20-s step toþ10 mV and the pre- and post-
pulse voltages were 10 mV. Recovery from inactivation
was determined by a train of postpulses (shown). The 20-s
inactivating pulse is not shown, but its position is indicated
by a dashed line after the prepulse in pulse protocol. (D)
The IPost/IPre is plotted versus recovery time for 20-s inac-
tivating data. Smooth lines are single exponential fits: t ¼
10.15 1.9 s and 12.55 1.8 s for ()PLM and (þ)PLM,
respectively (n ¼ 7, not significantly different). Asterisks
above data points indicates significant difference the frac-
tion of recovered current between () and (þ) PLM at
each time point.
1156 Wang et al.observed at potentials <0 mV. The voltage-dependence of
slowed activation may result from the concurrent PLM-
induced enhancement of inactivation that is more prevalent
at depolarized voltages. However, during preliminary muta-
genesis experiments we have identified PLM mutants that
fail to enhance VDI, but still selectively slow activation at
voltages <0 mV (K. Guo, X. Wang, G. Gao, C. Huang, K.
S. Elmslie, B. Z. Peterson, unpublished data). This supports
the idea that the PLM effect on activation is stronglyBiophysical Journal 98(7) 1149–1159voltage-dependent. Given that theC/O transition is voltage
independent (4,36), the mutation findings suggest that the
effect of PLM is to decrease the voltage-dependent C/ C
transitions, which predicts that CaV1.2 channel On-gating
currents will be slowed by PLM. Those experiments are
ongoing currently.
CaV1.2 channels have been shown to exhibit modal gating
behavior (31,40), where the channels exist in one of three
gating modes: mode 1 gating is characterized by shortFIGURE 7 Dynamic effects of PLM
on ionic flux. (A–E) Difference Ca2þ
currents (10 mM Ca2þ as charge carrier)
were calculated from averaged currents
(n ¼ 10–12) from cells recorded in the
absence and presence of PLM for 25 ms
at potentials from 10 to þ30 mV. (F)
Integrated difference currents (gray
shading) versus step voltage were used
to quantify voltage-dependent changes
in Ca2þ flux induced by PLM.
FIGURE 8 Cardiac action potential generated CaV1.2 currents are
increased by PLM. (A) Ca2þ currents generated by a human cardiac action
potential are superimposed from two cells in the absence (gray trace) or
presence (black trace) of PLM. The currents were normalized to the plateau
phase indicated by the first pair of vertical dashed lines. The second pair of
vertical dashed lines corresponds to the repolarization phase of the cAP
and marks the area over which the currents were integrated to determine
normalized charge (B). (B) Integration of the final 200 ms of cAP-generated
currents indicates that the fraction of current is increased during re-
polarization.
PLM-Induced Changes in CaV1.2 Gating 1157open times, low PO and represents the predominant mode of
gating; mode 2 gating occurs much less frequently and is
characterized by very long open times and high PO; and
mode 0 gating is observed when the channel fails to open
during a depolarizing step. Occupancy of mode 2 gating
greatly slows CaV1.2 channel deactivation as measured by
whole-cell tail currents (32,41,42) (5,43). Long depolariza-
tions that mimic the cardiac action potential can induce
CaV1.2 channels to switch from mode 1 into mode 2 gating
(32), but these depolarizations have only modest effects to
slow deactivation in HEK293 cells expressing CaV1.2 chan-
nels ()PLM. The coexpression of PLM significantly
enhances voltage-dependent slowing of deactivation so that
the channels appear to more closely mimic native L-channels
recorded from rat ventricular myocytes (32). Although singlechannel experiments are needed to confirm that PLM-
enhancement of slowed deactivation results from mode
switching, it seems likely that the interaction of PLM with
CaV1.2 channels in cardiac myocytes regulates the voltage-
and time-dependent mode switching to enhance Ca2þ influx.Role of PLM in regulating excitability
and contractility
The precise physiological role of PLM is not yet resolved
partly because the relationships between PLM and NKA
(6,15,44–47), NCX (7,48,49) and, as we report here,
CaV1.2 channels, are complex, and partly because there exists
some variability in the literature regarding the effect PLM
expression has on contractility (7,44,45,48,50). Results
from isolated myocytes suggest PLM induces a decrease in
contractile strength in low Ca2þ and has no effect on contrac-
tility in physiological Ca2þ (7,48,50). However, results from
whole heart suggest that PLM increases contractility in phys-
iological Ca2þ (45).
Our finding that PLM modulates the gating of cardiac
CaV1.2 channels further increases the complexity of the rela-
tionship between PLM expression and contractility. Changes
in calcium channel gating, such as impaired VDI and slowed
deactivation, profoundly affect cardiac function (2–4,34–
38,51). PLM-dependent slowed deactivation seems to
increase Ca2þ entry during the repolarization phase of the
cAP and may account for the observed decrease in left
ventricular pressure measured from PLM knockout mice
(45). In addition, by increasing the fraction of channels occu-
pying the deep inactivated state, PLM may help protect the
heart under conditions such as ischemia or tachycardia where
the channels undergo prolonged depolarization and the my-
ocytes are vulnerable to Ca2þ overload.SUPPORTING MATERIAL
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